Alloreactive donor and host immune cells in cord blood transplantation

This target refers to the complex interplay of donor-derived and recipient-derived immune cells following umbilical cord blood transplantation (UCBT). The primary components are alloreactive T cells, which can recognize foreign histocompatibility antigens, leading to either beneficial graft-versus-leukemia (GvL) effects or detrimental graft-versus-host disease (GvHD) (Zeiser & Blazar, 2017, NEJM). Cord blood grafts are unique due to the presence of more "naive" T cells compared to adult bone marrow, which generally results in a lower incidence of severe GvHD despite HLA mismatches (Ballen et al., 2013, Blood). Therapeutic strategies targeting these populations aim to selectively suppress alloreactive donor T cells while preserving regulatory T cells and anti-tumor effector cells (Hiwarkar et al., 2015, Blood). Management involves pharmacological immunosuppression and careful monitoring of hematopoietic chimerism to ensure successful engraftment and immune reconstitution (Baron et al., 2016, Biol Blood Marrow Transplant). The clinical goal is to achieve a state of tolerance where the donor immune system coexists with the host without causing systemic damage while still providing protection against infection and malignancy (Fuchs, 2017, Blood).

Other names

Alloreactive donor and host T cells and other hematopoietic/immune cell populations in cord blood graft and recipientDonor T cellsHost T cellsCord blood graft cellsAlloreactive lymphocytesHematopoietic stem cells

Immunosuppressive agents target these cell populations by inhibiting T-cell receptor signaling, blocking co-stimulation, or inducing direct cell depletion to prevent graft-versus-host disease (GvHD) while attempting to preserve graft-versus-leukemia (GvL) effects.